NASDAQ:AFMD
Affimed N.V. Stock News
$5.23
-0.140 (-2.61%)
At Close: Apr 17, 2024
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
02:08pm, Monday, 10'th Oct 2022 Benzinga
Upgrades
OTR Global upgraded the previous rating for Restaurant Brands International Inc (NYSE:QSR) from Mixed to Positive. For the second quarter, Restaurant Brands Intl had an EPS of $0.82, compared
Ford To Plunge 18%? Plus Mizuho Predicts $149 For PPG Industries
01:59pm, Monday, 10'th Oct 2022 Benzinga
SVB Leerink raised Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) price target from $5 to $15. Satsuma Pharmaceuticals shares rose 15.7% to trade at $6.20 on Monday.
UBS cut Ford Motor Company (NYSE
Domino's Pizza To $375? Plus Stifel Cuts Price Target On This Stock By Around 78%
12:52pm, Monday, 10'th Oct 2022 Benzinga
Credit Suisse cut the price target on Domino's Pizza, Inc. (NYSE: DPZ) from $425 to $375. Domino's shares fell 0.3% to $313.70 in pre-market trading.
Barclays slashed the price target for Argo Block
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
12:05pm, Wednesday, 05'th Oct 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
10:05pm, Sunday, 04'th Sep 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,
Affimed to Present at Upcoming Investor Conferences
10:30am, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t
Affimed to Present at Upcoming Investor Conferences
06:30am, Thursday, 01'st Sep 2022
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back the
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
11:58am, Wednesday, 24'th Aug 2022 The Motley Fool
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
Affimed NV (AFMD) CEO Adi Hoess on Q2 2022 Results - Earnings Call Transcript
12:44pm, Thursday, 11'th Aug 2022
Affimed NV (NASDAQ:AFMD ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Alexander Fudukidis - Head, IR Adi Hoess - CEO Angus Smith - CFO Andreas Harstrick - Chief Me
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
11:45am, Thursday, 11'th Aug 2022 Zacks Investment Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
10:30am, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back th
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
09:02am, Thursday, 11'th Aug 2022
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022.
Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates
11:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 5.13% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Monday, 08'th Aug 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
10:30am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back t